Radiaction Medical Raises Series C2 Funding

August 29, 2023—Radiaction Medical, Ltd., an Israel-based medical device company focused on radiation protection during interventional procedures, announced it has raised $12.6 million in Series C2 funding, led by United States private equity fund InnovaHealth Partners with participation from additional coinvestors.

Additionally, the company has elected Christopher Barys to serve on its Board of Directors. Barys joins the company with more than 30 years of medical device sales, marketing, and business experience, including leadership in the cardiac catheterization and image-guided spaces.

According to the company, the Radiaction system is designed as a plug-and-play addition to C-arm systems that blocks up to 97% of scatter radiation at the source, providing head-to-toe radiation protection to the entire interventional team while allowing unencumbered patient care, access, and service. Radiaction has received CE Mark approval and FDA clearance and is being marketed in North America.

Radiaction stated it is expanding its footprint in the United States, adding new sites to its user base, providing key support staff to ensure the success of each system installation, developing additional features, and growing its clinical publication pipeline to support the technology’s performance with clinical data.

Radiaction CEO Jonathan Yifat commented in the press release, “This current financing round is a significant step forward, one that enables us to expand our reach further, lead with exceptional customer support, and provide this essential technology to protect those who care for patients.”

Yifat added, “The addition of Christopher Barys is a tremendous asset to the strategic composition of our Board of Directors. Chris has a proven track record of market development and growth within the interventional space we aim to serve. He brings a keen eye for strategic opportunities and will help guide our company through its next stages of growth.”